Coiled Therapeutics shares rise as cross trading begins in New York

(Alliance News) - Coiled Therapeutics PLC on Tuesday reported its US trading launch.

The London-based clinical stage oncology company will start trading on the OTCQB Venture Market in New York on Tuesday, under the ticker 'COTXF'.

It will continue to trade in London under the ticker 'COIL'.

The company's shares rose 8.7% on Tuesday afternoon to 9.52 pence each in London and are up 2.9% over the past year.

"Cross trading on the OTCQB market allows the company to access one of the world's largest investment markets to expand its reach into a broader pool of investors," Coiled noted.

Chief Executive Sridhar Vempati commented: "This is an exciting time for the company, following the highly encouraging clinical data from Cohort 4b in our ongoing clinical trial, which delivered an 80% clinical benefit rate and durable responses in a heavily pre-treated patient population. With dose escalation on track for completion in H1 2026 and multiple data catalysts ahead, we believe 2026 will be a transformational year for Coiled Therapeutics, and we look forward to welcoming new US investors as we deliver on our clinical and strategic milestones."

By Holly Munks, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Coiled Thera